Follow the Apexigen, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was disclosed on 25 August 2023 (Retenue fiscale). Among the most active insiders: Sarena Francis Willard. Every trade is openly available.
26
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Apexigen, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
29Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Apexigen, Inc. is a biopharmaceutical company focused on developing immuno-oncology treatments. It utilizes its drug discovery platform to create therapeutic antibodies targeting tumors.